(RF) Eurazeo - Overview

Sector: Financial Services | Industry: Asset Management | Exchange: PA (France) | Market Cap: 3.079m EUR | Total Return: 36.6% in 12m

Private Equity, Venture Capital, Real Estate, Asset Management
Total Rating 21
Safety 18
Buy Signal -0.22
Asset Management
Industry Rotation: -2.1
Market Cap: 3.58B
Avg Turnover: 3.60M
Risk 3d forecast
Volatility27.6%
VaR 5th Pctl4.87%
VaR vs Median7.42%
Reward TTM
Sharpe Ratio-0.76
Rel. Str. IBD52.3
Rel. Str. Peer Group25
Character TTM
Beta0.942
Beta Downside1.086
Hurst Exponent0.574
Drawdowns 3y
Max DD53.15%
CAGR/Max DD-0.15
CAGR/Mean DD-0.42

Warnings

No concerns identified

Tailwinds

No distinct edge detected

Description: RF Eurazeo

Eurazeo SE (RF) is a diversified global investment firm managing a broad portfolio across private equity, venture capital, and real estate. The firm targets a range of investment stages, from growth capital and Series C rounds to large-scale leveraged buyouts and mid-market acquisitions. Its geographic focus spans Europe, North America, and China, with a strategic emphasis on sectors undergoing digital transformation or shifts in consumer lifestyle, such as fintech, healthcare, and luxury goods.

Operating within the alternative asset management sector, Eurazeo utilizes a permanent capital model which allows for longer holding periods compared to traditional fixed-life private equity funds. This structure facilitates value creation through operational restructuring and international expansion, particularly in the upper mid-market segment where the firm deploys significant capital into differentiated business concepts. Detailed performance metrics and portfolio holdings are available on ValueRay for those conducting further analysis.

Headlines to Watch Out For
  • Asset management fee growth driven by rising third-party capital commitments
  • Private equity exit environment volatility impacts net asset value and realizations
  • Interest rate fluctuations influence cost of debt for leveraged buyout portfolio
  • European economic performance dictates valuation multiples for mid-market industrial and consumer holdings
  • Fundraising momentum across healthcare and technology sectors determines future management margins
Piotroski VR-10 (Strict) 2.0
Net Income: -833.8m TTM > 0 and > 6% of Revenue
FCF/TA: 0.01 > 0.02 and ΔFCF/TA 1.38 > 1.0
NWC/Revenue: -127.6% < 20% (prev -12.87%; Δ -114.7% < -1%)
CFO/TA 0.01 > 3% & CFO 111.8m > Net Income -833.8m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 0.36 > 1.5 & < 3
Outstanding Shares: last quarter (52.8m) vs 12m ago -28.33% < -2%
Gross Margin: -28.90% > 18% (prev 0.67%; Δ -2.96k% > 0.5%)
Asset Turnover: 5.51% > 50% (prev 58.73%; Δ -53.22% > 0%)
Interest Coverage Ratio: -23.90 > 6 (EBITDA TTM -817.4m / Interest Expense TTM 35.6m)
Altman Z'' 5.25
A: -0.08 (Total Current Assets 351.3m - Total Current Liabilities 982.1m) / Total Assets 8.19b
B: 0.74 (Retained Earnings 6.08b / Total Assets 8.19b)
C: -0.09 (EBIT TTM -849.8m / Avg Total Assets 8.98b)
D: 3.78 (Book Value of Equity 6.40b / Total Liabilities 1.70b)
Altman-Z'' = 5.25 = AAA
Beneish M 1.00
DSRI: 7.87 (Receivables 191.6m/282.3m, Revenue 494.4m/5.74b)
GMI: 1.00 (fallback, negative margins)
AQI: 1.00 (AQ_t 0.95 / AQ_t-1 0.95)
SGI: 0.09 (Revenue 494.4m / 5.74b)
TATA: -0.12 (NI -833.8m - CFO 111.8m) / TA 8.19b)
Beneish M = 1.86 (Cap -4..+1) = D
What is the price of RF shares?

As of May 24, 2026, the stock is trading at EUR 45.14 with a total of 59,629 shares traded.
Over the past week, the price has changed by +4.39%, over one month by -2.01%, over three months by -2.13% and over the past year by +36.60%.

Is RF a buy, sell or hold?

Eurazeo has no consensus analysts rating.

Eurazeo (RF) - Fundamental Data Overview as of 24 May 2026
Market Cap USD = 3.58b (3.08b EUR * 1.1625 EUR.USD)
P/E Forward = 15.4321
P/S = 71.8477
P/B = 0.4951
P/EG = 0.0293
Revenue TTM = 494.4m EUR
EBIT TTM = -849.8m EUR
EBITDA TTM = -817.4m EUR
Long Term Debt = 199.3m EUR (from longTermDebt, last quarter)
Short Term Debt = 982.1m EUR (from shortTermDebt, last quarter)
Debt = 1.33b EUR (from shortLongTermDebtTotal, last quarter) + Leases 79.6m
Net Debt = 1.22b EUR (calculated: Debt 1.33b - CCE 114.8m)
Enterprise Value = 4.29b EUR (3.08b + Debt 1.33b - CCE 114.8m)
Interest Coverage Ratio = -23.90 (Ebit TTM -849.8m / Interest Expense TTM 35.6m)
EV/FCF = 45.50x (Enterprise Value 4.29b / FCF TTM 94.4m)
FCF Yield = 2.20% (FCF TTM 94.4m / Enterprise Value 4.29b)
FCF Margin = 19.09% (FCF TTM 94.4m / Revenue TTM 494.4m)
Net Margin = -168.6% (Net Income TTM -833.8m / Revenue TTM 494.4m)
Gross Margin = -28.90% ((Revenue TTM 494.4m - Cost of Revenue TTM 637.3m) / Revenue TTM)
Gross Margin QoQ = -71.67% (prev none%)
Tobins Q-Ratio = 0.52 (Enterprise Value 4.29b / Total Assets 8.19b)
Interest Expense / Debt = 2.67% (Interest Expense 35.6m / Debt 1.33b)
Taxrate = 25.0% (EU avg default 25%)
NOPAT = -637.4m (EBIT -849.8m * (1 - 25.00%)) [loss with tax shield]
Current Ratio = 0.36 (Total Current Assets 351.3m / Total Current Liabilities 982.1m)
Debt / Equity = 0.21 (Debt 1.33b / totalStockholderEquity, last quarter 6.25b)
 Debt / EBITDA = -1.49 (negative EBITDA) (Net Debt 1.22b / EBITDA -817.4m)
 Debt / FCF = 12.88 (Net Debt 1.22b / FCF TTM 94.4m)
Total Stockholder Equity = 6.95b (last 4 quarters mean from totalStockholderEquity)
RoA = -9.29% (Net Income -833.8m / Total Assets 8.19b)
RoE = -11.99% (Net Income TTM -833.8m / Total Stockholder Equity 6.95b)
RoCE = -11.88% (EBIT -849.8m / Capital Employed (Equity 6.95b + L.T.Debt 199.3m))
 RoIC = -7.89% (negative operating profit) (NOPAT -637.4m / Invested Capital 8.07b)
 WACC = 7.09% (E(3.08b)/V(4.41b) * Re(9.29%) + D(1.33b)/V(4.41b) * Rd(2.67%) * (1-Tc(0.25)))
Discount Rate = 9.29% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -46.67 | Cagr: -13.10%
[DCF] Terminal Value 75.44% ; FCFF base≈94.4m ; Y1≈94.8m ; Y5≈100.4m
[DCF] Fair Price = 5.38 (EV 1.56b - Net Debt 1.22b = Equity 345.6m / Shares 64.3m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: -90.93 | Revenue CAGR: -77.44% | SUE: 0.02 | # QB: 0
EPS current Year (2026-12-31): EPS=4.82 | Chg30d=-29.15% | Revisions=-20% | GrowthEPS=+186.9% | GrowthRev=+34.1%
EPS next Year (2027-12-31): EPS=10.17 | Chg30d=-5.72% | Revisions=-33% | GrowthEPS=+110.9% | GrowthRev=+35.7%
[Analyst] Revisions Ratio: -33%